CASE REPORT

‘Smoke in the air’: a rare cerebrovascular cause of neurological signs and symptoms in a young adult

Imtiaz Ismail, MD1*, Khalid Al-Khafaji, MD1, Monica Mutyala, MD1, Saurabh Aggarwal, MD2, Nawfal Al-Khafaji, MD1, Daniela Kovacs, MD1, Sandeep Khosla, MD1 and Rohit Arora, MD1

1Department of Internal Medicine, Rosalind Franklin University of Medicine and Science, Waukegan, IL, USA; 2Department of Cardiology, Creighton University, Omaha, NE, USA

Moyamoya disease is a rare neurological condition that affects children and adults of all ages. It is characterized by chronic, progressive stenosis of the circle of Willis that ultimately leads to the development of extensive collateral vessels. Presenting symptoms are usually due to cerebral ischemia or hemorrhage. The Japanese term moyamoya (meaning puffy or obscure) was coined to describe the characteristic ‘smoke in the air’ appearance of these vessels on cerebral angiography. Moyamoya has the highest recorded incidence in Japan (0.28 per 100,000). In the west it is an extremely rare condition with an overall incidence of (0.086 per 100,000) in the Western United States. Etiology for the most part is unknown; however, genetic susceptibility related to RNF213 gene on chromosome 17q25.3 has been suggested. Moyamoya is being diagnosed more frequently in all races with varying clinical manifestations. Moyamoya disease is a rare progressive neurologic condition characterized by occlusion of the cerebral circulation with extensive collaterals recruitment in children and adults. Distinguished radiological findings confirm the diagnosis. Early recognition and swift institution of therapy is vital in order to minimize neurological deficits. We present the case of a 19-year-old African American female who presented with left-sided paraesthesia, weakness, and headache for 2 days duration.

Keywords: Moyamoya; neurology; Japanese; circle of Willis; collaterals; smoke

*Correspondence to: Imtiaz Ismail, Captain James A. Lovell Federal Health Care Center, Rosalind Franklin University of Medicine and Science, 4528 W Quill Lane, Waukegan, IL 60085, USA, Email: imtuismail@gmail.com

Received: 19 February 2015; Revised: 11 April 2015; Accepted: 14 April 2015; Published: 15 June 2015

We present the case of a 19-year-old African American female who presented with left-sided paraesthesia, weakness, and headache for 2 days duration. Her past medical history was significant for four syncopal episodes lasting less than 30 sec, for which the patient did not seek medical attention. Physical exam revealed decreased light touch and proprioception in the left lower extremity. Laboratory tests including complete blood count (CBC), basic metabolic profile, urine drug screen, and thyroid functions were within normal limits.

Computerized tomography of head showed multiple small foci of hypoattenuation in the right periventricular white matter. Contrast magnetic resonance imaging of the brain showed scattered areas of T2 hyper intense signal within the white matter of the right cerebral hemisphere in the ‘watershed areas’ (Fig. 1). Additional laboratory tests including erythrocyte sedimentation rate (ESR), C-reactive protein, and lupus anticoagulant were normal. The patient was diagnosed with moyamoya disease and was started on aspirin therapy. She has been followed up quarterly and has shown improvement in her neurologic symptoms. She is currently doing well and has not had any further episodes of syncope.

Moyamoya disease (MMD) is a rare neurological condition that affects children and adults of all ages. It is characterized by chronic, progressive stenosis of the circle of Willis that ultimately leads to the development of extensive collateral vessels. Presenting symptoms are usually due to cerebral ischemia or hemorrhage. The Japanese term moyamoya (meaning puffy or obscure) was coined to describe the characteristic ‘smoke in the air’ appearance of these vessels on cerebral angiography.

MMD has the highest recorded incidence in Japan (0.28 per 100,000). In the west it is an extremely rare condition with an overall incidence of (0.086 per 100,000) in the United States. Etiology for the most part is unknown; however, genetic susceptibility related to RNF213 gene on chromosome 17q25.3 has been suggested. MMD is being diagnosed more frequently in all races with varying clinical manifestations.
protein (CRP), Antinuclear antibodies (ANA), Cytoplasmic antineutrophil cytoplasmic antibodies (c-ANCA), Perinuclear antineutrophil cytoplasmic antibodies (p-ANCA), protein C and S, antithrombin III, homocysteine, factor V Leiden, coagulation profile, rapid plasma reagin (RPR), HIV, vitamin B12, folate, and a lumbar puncture were all within normal limits.

Magnetic resonance angiography of the brain revealed near occlusion of the distal supraclinoid segment of the right internal carotid artery (ICA) with extensive collateral augmentation (Fig. 2).

Conventional angiography of the head and neck was performed which confirmed the occlusion. Also revealed was a moyamoya-like conversion of the lenticulostriate
arteries giving a classic ‘puff of smoke’ appearance (Fig. 3). Based on this, patient was diagnosed with Moyamoya disease. She then underwent neurosurgical anastomosis of the right superficial temporal artery to the right middle cerebral artery.

**Discussion**

Moyamoya disease (MMD) is a chronic idiopathic neurovascular occlusive disorder that was first described in 1957 by Takeuchi and Shimizu (1). It is characterized by progressive occlusion of the ICA and circle of Willis, leading to formation of collateral small vessels at the base of the brain to compensate the reduced blood flow from arterial stenosis (1). Moyamoya, which means ‘puff of smoke’ in Japanese, describes the hazy appearance of the abnormal vascular network seen on cerebral angiography (2).

The etiology of MMD is unknown; however, it has been suggested that the onset of the disease can be contributed to genetic, ethnic, and environmental factors (3). There has been a strong link to MMD in Japan and Korea with RNF213, which is a MMD susceptible gene found on chromosome 17q25.3, and mutation p.R4859K (4). MMD is more commonly seen in East Asia, particularly Japan, than Europe and the Americas (7, 8). It has been noted that there is a female predominance (9, 10) with a bimodal age distribution involving the first and fourth decade of life (10–13).

The clinical presentation of MMD varies between children and adults. In children, MMD presents with repetitive transient ischemic attacks (TIA) and cerebral infarction. Other symptoms seen in pediatric patients can include episodes of seizures, headaches, strokes, or focal neurological deficits (14). In adults, cerebral hemorrhage, in the intraventricular region, is a common symptom while it is uncommon in children (15). Cerebral ischemia is another presentation seen in adult patients and has been noted to affect the ‘watershed’ territories of the brain (1).

The main diagnostic imaging studies for MMD include magnetic resonance imaging (MRI), magnetic resonance angiography (MRA), and cerebral angiography. The MRI and MRA are noninvasive imaging studies in MMD that demonstrate steno-occlusive disease of the terminal ICA, the proximal portions of the anterior and middle cerebral arteries, and basal moyamoya vessels, which is the abnormal vascular network in the vicinity of the stenosis or occlusion (16). When the described findings are seen bilaterally on MRI and MRA, it is a definitive diagnosis of MMD and does not require cerebral angiography, while probable diagnosis of MMD is noted if the findings are seen unilaterally (1). Conventional angiography is the gold standard for diagnosis of MMD. It demonstrates fine basal collaterals giving the classic ‘puff of smoke’ appearance (2). In our case, the MRI showed ‘watershed areas’ having hyper tense signal within the white matter demonstrating cerebral ischemia, and the conventional angiography of the head and neck in our patient revealed the classic ‘puff of smoke’ from the conversion of the lenticulostriate arteries.

The mainstay of treatment for MMD is surgical revascularization. Medical treatment has not been proven to be effective (17). Cerebral revascularization techniques include direct and indirect surgical techniques. In the adult population, direct revascularization has proven to be more effective, while in the pediatric patients indirect approach is more successful (1). In adults with MMD having cerebral ischemia, it is recommended that direct arterial bypass with possible indirect surgical techniques is carried out (1).

**Conclusion**

Moyamoya disease is a rare progressive neurologic condition characterized by occlusion of the cerebral circulation with extensive collaterals recruitment in children and adults. Distinguished radiological findings confirm the diagnosis. Early recognition and swift institution of therapy is vital in order to minimize neurological deficits. This case emphasizes that moyamoya, despite being extremely rare, even more so in African American’s, should be
considered in any patient with unexplained neurological symptom indicative of cerebral ischemia.

Conflict of interest and funding

The author has not received any funding or benefits from industry or elsewhere to conduct this study.

References

1. Zipfel GJ, Fox DJ, Rivet DJ. Moyamoya disease in adults: The role of cerebral revascularization. Skull Base 2005; 15: 27–41. doi: 10.1055/s-2005-868161.
2. Suzuki J, Takaku A. Cerebrovascular ‘moyamoya’ disease. Disease showing abnormal net-like vessels in base of brain. Arch Neurol 1969; 20: 288–99.
3. Houkin K, Kiyohiro, Ito M, Sugiyama T, Shichinohe H, Nakayama N, et al. Review of past research and current concepts on the etiology of moyamoya disease. Neurol Med Chir 2012; 52: 267–77.
4. Morito D, Nishikawa K, Hoseki J, Kitamura A, Kotani Y, Kiso K, et al. Moyamoya disease-associated protein mysterin/RNF213 Is a Novel AAA+ ATPase, which dynamically changes its Oligomeric State. Sci Rep 2014; 4: 442. doi: 10.1038/srep04442.
5. Kamada F, Aoki Y, Narisawa A, Abe Y, Komatsuzaki S, Kikuchi A, et al. A genome-wide association study identifies RNF213 as the first moyamoya disease gene. J Hum Genet 2011; 56: 34–40. doi: 10.1038/jhg.2010.132.
6. Liu W, Morito D, Takashima S, Mineharu Y, Kobayashi H, Hitomi T, et al. Identification of RNF213 as a susceptibility gene for moyamoya disease and its possible role in vascular development. PLoS One 2011; 6: e22542. doi: 10.1371/journal.pone.0022542.
7. Kuroda S, Houkin K, Moyamoya disease: Current concepts and future perspectives. Lancet Neurol 2008; 7: 1056–66. doi: 10.1016/S1474-4422(08)70240-0.
8. Yonekawa Y, Ogata N, Kaku Y, Taub E, Imhof HG. Moyamoya disease in Europe, past and present status. Clin Neurol Neurosurg 1997; 99: S58–60.
9. Wakai K, Tamakoshi A, Ikezaki K, Fukui M, Kawamura T, Aoki R, et al. Epidemiological features of moyamoya disease in Japan: Findings from a nationwide survey. Clin Neurol Neurosurg 1997; 99: S1–5.
10. Suzuki J, Kodama N. Moyamoya disease: A review. Stroke 1983; 14: 104–9.
11. Maki Y, Enomoto T. Moyamoya disease. Childs Ner Syst 1988; 4: 204–12.
12. Kudo T, Fukuta S. Spontaneous occlusion of the circle of Willis. Shinkei Shimp 1976; 20: 750–7.
13. Kudou T. Obstruction of circle of Willis: Moyamoya disease. Int Med 1977; 28: 465–9.
14. Joshi G. Moya moya disease: Presenting with changing neurological signs. JKIMSU 2014; 3(1): 116–19.
15. Handa H, Yonekawa Y, Goto Y. Analysis of the filing data bank of 1500 cases of spontaneous occlusion of the circle of Willis and follow-up study of 200 cases for more than five years. In: Handa H, ed. Annual report (1984) by research committee on spontaneous occlusion of the circle of Willis. Tokyo, Japan: Ministry of Health and Welfare; 1985, pp. 4–22.
16. Houkin K, Aoki T, Takahashi A, Abe H. Diagnosis of moyamoya disease with magnetic resonance angiography. Stroke 1994; 25: 2159–64.
17. Suzuki J. Moyamoya disease. Tokyo, Japan: Springer-Verlag; 1986.